Relevium Technologies (TSXV:RLV,OTC:RLLVF;FWB:6BX) has launched its campaign on the Investing News Network’s cannabis channel.

Relevium Technologies is developing a portfolio of brands, products and technologies in the health and wellness market. The company has assets in the United States and the United Kingdom with plans to expand into international markets including Canada and Latin America. The company is developing four brands which are offered through its two subsidiaries: BioGanix and Biocannabix. BioGanix is the parent company for a variety of weight-loss, health, beauty and fitness supplements. Together the brands under the BioGanix label generate over $1 million in revenue per quarter.


Biocannabix aims to serve the pediatric and adult markets with nutraceutical and pharmaceutical cannabis-based products available in the United States and Europe. Relevium has launched LeefyLyfe, a hemp-based product line, to consumers in the UK under its Biocannabix brand. Biocannabix has secured a 93,000-square-foot organic cultivation and processing facility in Montreal, Quebec. Once complete, the facility is expected to be home to Relevium’s research and development facilities.

Relevium Technologies’ company highlights include the following:

  • Global cannabis market to surpass $31 billion by 2021.
  • In 2017, the global wellness market reached $4.2 trillion.
  • Global nutraceutical market to reach US$578.23 billion by 2025.
  • Vast distribution network through industry giants like Walmart and Amazon.
  • Building out 93,000-square-foot cannabis cultivation and processing facility in Montreal, Quebec.
  • BioGanix generates approximately $1 million in revenue per quarter.
  • 47 SKUs developed for BioGanix to date.
  • Acquiring Cannakids’s IP, a leader in medical cannabis patient research and pediatric and adult consumer product development.
  • Pending Sleipnir acquisition will initially bring in US$500,000 to Relevium’s topline revenue.
  • Partnership in place with HempCo Canada.
  • International expansion plans for all brands.

Click here to see the educational profile for Relevium Technologies and to request an investor presentation.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less